Vanguard Fiduciary Trust
TGTX icon

Vanguard Fiduciary Trust’s TG Therapeutics TGTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.8M Sell
961,750
-6,916
-0.7% -$283K 0.01% 833
2026
Q1 		$32.2M Buy
+968,666
New +$28.9M 0.01% 1029

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Fiduciary Trust's TGTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its TG Therapeutics (TGTX) stake by 0.71% in Q2 2026, selling an estimated $283K and leaving 961,750 shares worth $52.8M. The position accounts for 0.01% of the portfolio, ranked #833.

Vanguard Fiduciary Trust first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 961,750 shares of TG Therapeutics worth $52.8M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 6,916 TG Therapeutics shares in Q2 2026, an estimated $283K.
  • TG Therapeutics made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #833 holding.
  • Vanguard Fiduciary Trust first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.